GE, Clarient Move MultiOmyx Platform into Clinic with Launch of Hodgkin Diagnostic | GenomeWeb

With the launch this month of its Hodgkin Lymphoma Profile diagnostic, GE Healthcare has moved its MultiOmyx protein detection system into the clinical arena.

Offered through the company's Clarient Diagnostic Services, the HL Profile test assesses the levels of nine proteins linked to Hodgkin, and is intended as an aid to diagnose the disease where conventional methods are either impractical or insufficient.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.